Abstract: Described herein are methods and compositions for detecting, amplifying and labeling targeted nucleic acids, including microRNAs.

Abstract: Diagnostic methods for assessing risk of or presence of inflammatory bowel disease in a patient based on glycosyltransferase or histo-blood group antigen signatures or a combination thereof. Also disclosed herein are prognostic methods for monitoring inflammatory bowel disease progression in a patient.

Abstract: A method and system to determine biomarkers related to abnormal condition in a subject are provided, comprising:sequencing nucleic acid samples from a first and a second subject in order to obtain multiple sequences respectively consisting of the first and the second sequencing results, wherein the first subject is in the abnormal condition; and the second subject is not in the abnormal condition; and the nucleic acid samples from the first and the second subject are both isolated from the samples of the same type; and the first and the second subject belong to the same species; and determining the biomarkers related to the abnormal condition in the subject based on the difference between the first and the second sequencing results.

Abstract: Use of gene expression profiles obtained in vitro from a patient's sample for establishing the local infection of a “fever of unknown origin”, wherein the gene expression profiles are specific for local inflammations of a “fever of unknown origin”, such as peritonitis, pneumonia, endocarditis or infections of the urea tract.

Abstract: Methods of sepsis in a sample from a patient are provided. Methods of detecting changes in expression of one or more RNAs associated with sepsis are also provided. Compositions and kits are also provided.

Abstract: The present disclosure relates to methods, compositions and systems for haplotype phasing and copy number variation assays. Included within this disclosure are methods and systems for combining the barcode comprising beads with samples in multiple separate partitions, as well as methods of processing, sequencing and analyzing barcoded samples.

Abstract: The present invention relates to methods and uses of FcRL4 expression and optionally RANKL expressing B cells as biomarkers and therapeutic target for treatment of an autoimmune and/or chronic diseases associated with joint inflammation, in particular Rheumatoid Arthritis (RA).

Abstract: The present invention relates to methods for assessing the risk of a dog to develop canine atopic dermatitis. The methods comprise detecting in a sample of DNA obtained from a dog the presence or absence of at least one genetic marker, wherein said at least one genetic marker is located on dog (Canis familiaris) chromosome 27, said marker being associated with an increased risk of developing canine atopic dermatitis.

Abstract: The present invention relates to systems and methods for predicting an individuals likely response to a pain medication comprising genotyping genetic variations in an individual to determine the individual's propensity for metabolizing a pain medication and likely response to a medication, and preferably diverse reactions to a medication. In particular, the invention comprises analyzing a biological sample provided by an individual, typically a patient or an individual diagnosed with a particular disorder, determining the individual's likely response to a particular treatment, more specifically a pain medication, and thereafter displaying, or further, recommending a plan of action or inaction. In particular, the present invention provides a grading method and system to profile an individual's response to one or more pain medication.

Abstract: The disclosed methods, assays and kits identify biomarkers, particularly miRNA and/or protein biomarkers, for assessing the cardiovascular health of a human. In certain embodiments, methods, assays and kits, circulating miRNA and/or protein biomarkers are identified for assessing the cardiovascular health of a human.

Abstract: The present invention provides methods for predicting the pattern of locomotion in a horse including the ability of a horse to use different gaits and the ability to trot at a fast speed. The methods comprise determining in a sample of DNA obtained from a horse the presence or absence of at least one genetic marker, wherein said at least one genetic marker is located on horse chromosome 23, said marker being associated with the ability to use different gaits. The invention further provides primers that amplify markers being associated with the ability to use different gaits and hybridization probes to detect markers being associated with the ability to use different gaits and the ability to trot at a fast speed.

Abstract: A method for measuring blood levels of ? cell DNA that is released upon ? cell death by using a quantitative probe technology to detect amplified methylated and demethylated forms of the insulin gene DNA, representing normal tissue and ? cell specific origin, respectively. Using probes permits the sensitive and specific identification of demethylated insulin DNA patterns that are present only in ? cells. The method offers a bioassay for detecting ? cell loss in diabetes, useful for screening of prediabetes, monitoring of disease progression, and selection and monitoring of therapies. The technique finds potential use in both Type I and Type II diabetes, as well as gestational diabetes.

Abstract: The present invention also provides various methods, kits and compositions for diagnosing, prognosing, and treating various conditions including but not limited to inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. Also, the present invention provides various methods, kits and compositions for determining susceptibility to or a low probability of various conditions including but not limited to inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. These methods, kits and compositions may involve detecting risk/protective variants or haplotypes, serological markers, increased or decreased gene methylation, and increased or decreased cytokine secretion.

Abstract: A method for determining the presence or absence of a genetic segment of interest, such as an exon, an intron or a promoter, in a DNA-containing sample, and probe sets for use in such methods, including probe sets comprising oligonucleotide probes having nucleotides sequences selected from those of SEQ ID NOS: 1-101.

Abstract: A nucleic acid normalization kit can include a nucleic acid having a normalization sequence including or complementary to one or more of SEQ ID NOs: 1-4 and 301-303 or unique segment thereof, the nucleic acid being present in an amount sufficient for use in a nucleic acid normalization protocol. The normalization kit can be used in a method of identifying a pregnancy normalization nucleic acid sequence. A nucleic acid diagnostic kit for diagnosing susceptibility to preterm birth (PTB) can include a nucleic acid having a CFP RNA PTB biomarker sequence including or complementary to one or more of SEQ ID NOs: 5-300 or unique segment thereof, the nucleic acid being present in an amount sufficient for use in a nucleic acid diagnostic protocol for diagnosing susceptibility to PTB. The diagnostic kit can be used in a method for predicting susceptibility of a pregnant woman to preterm birth (PTB).

Abstract: A method of evaluating a cancer patient comprising evaluating gene expression levels in a patient sample, calculating a predictor score using the gene expression levels, and assessing the likelihood of a therapeutic outcome using the predictor score is disclosed.

Abstract: Methods of lung cancer in a sample from a patient are provided. Methods of detecting changes in expression of one or more target RNAs associated with lung cancer are also provided. Compositions and kits are also provided.

Abstract: In one embodiment, a method of theranostic classification of a breast cancer tumor is provided, comprising obtaining a breast cancer tumor sample from a subject, detecting an expression level of FOXC1, comparing the expression level of FOXC1 to a predetermined cutoff level, and classifying the breast cancer tumor sample as belonging to a theranostic basal-like breast cancer tumor subtype or a theranostic hybrid basal-like breast cancer tumor subtype when the expression level of FOXC1 is higher than the predetermined cutoff level.

Abstract: Biomarkers, methods, assays, and kits are provided for predicting the efficacy of adjuvant chemotherapy (ACT) in a subject with early-stage non-small cell lung cancer (NSCLC).

Abstract: A method for predicting a benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer.

Abstract: Provided herein is an analytical method for determining whether a hepatocellular carcinoma patient has susceptibility or resistance to sorafenib treatment by analyzing the mRNA expression of FGFR1, optionally along with the mRNA expressions of other biomarkers (i.e., VEGFR2, PDGFR?, c-KIT, c-RAF, EGFR, and/or mTOR) to select a patient having susceptibility to sorafenib treatment and a patient having resistance to sorafenib treatment before employing molecular targeted therapy with sorafenib.

Abstract: The present invention provides a method capable of detecting a cancer and/or a carcinogenic risk, and a reagent for the detection thereof. The present invention also provides a method for screening for a pharmaceutical drug for reducing a carcinogenic risk and a pharmaceutical composition. Since cancer development closely correlates with alteration in gut microbiota, cancer development and/or a risk of cancer development are detected by detecting alteration in gut microbiota and a secondary bile acid produced by an intestinal bacterium. The present invention further provides a method for screening for a pharmaceutical drug with a gut microbiota as an index, and a pharmaceutical composition.

Abstract: This invention is directed to a method for detecting melanoma in a tissue sample by measuring a level of methylation of one or more regulatory elements differentially methylated in melanoma and benign nevi. The invention provides methods for detecting melanoma, related kits, and methods of screening for compounds to prevent or treat melanoma.

Abstract: The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen.

Abstract: The invention relates to the field of quality testing of fresh plant-based and mushroom based products. Methods, carriers and kits for determining the quality stage are provided.

Abstract: The current invention provides a method for rapid testing of stress tolerance in a plant and a method of producing plants with enhanced stress tolerance, in particular cold and/or drought tolerance. Such a method may be applied in breeding and selection programs for this trait, or for determining the timing of induction of stress and cold tolerance or hardening of a plant, for instance for agricultural purposes. The current invention exploits a difference in the temperature and light regimen induced transcriptional regulation of several types of dehydrins, in order to determine a ratio of dehydrin types that is indicative of cold and/or drought tolerance, induction of hardening and dormancy in a plant.

Abstract: Disclosed herein are methods, compositions and kits for the quantification of a nucleic acid target present on a solid support. This entails quantitative real-time polymerase chain reaction wherein minor groove binders are excluded.

Abstract: Provided herein are compositions, methods, and kits for detecting human Pegivirus 2 (HPgV-2). In certain embodiments, provided herein are HPgV-2 specific nucleic acid probes and primers, and methods for detecting HPgV-2 nucleic acid. In other embodiments, provided herein are HPgV-2 immunogenic composition compositions, methods of treating a subject with immunogenic HPgV-2 peptides, and methods of detecting HPgV-2 subject antibodies in a sample.

Abstract: Described are biomarkers and associated methods for identifying a subject having, or at risk of developing, severe illness from influenza. The level of one or more biomarkers in a test sample from the subject is determined and compared to a control level. Optionally, the subject has or is suspected of having H1N1 influenza. In some embodiments the biomarkers may include IL23R, IL10, TNFRSF13B, CX3CR1, CCR2, MAP2K3 and/or IRF1. In some embodiments, the biomarkers include a combination of IL2 and IL23R or IL10 and IL23R. Also described are methods which include determining the level of two or more biomarkers in a sample and multivariate methods are used for comparing the levels in the test sample to the level in a control sample.

Abstract: A method for identifying a risk factor for diseases, disorders or conditions, such as those caused by human immunodeficiency virus, using the polymerase chain reaction and specific primers. Methods for treating patients having these diseases, disorders or conditions by antimicrobial treatment of the risk factor by combined antiviral and antibacterial treatment or by sustaining or stimulating the subject's immune system. Methods for screening biological products including red blood cell preparations. Primers and methods for detecting nucleic acids or microbial agents associated with red blood cells, such as those associated with red blood cells in subjects infected with HIV and undergoing antiretroviral therapy.

Abstract: The disclosure provides compositions and methods for the detection of human papillomavirus (HPV) nucleic acids in a urine sample from a human subject. The nucleic acids may be from one or more high risk forms of HPV. The urine sample is minimally processed, without fractionation into cell-free and cell-containing portions, before preparation of the nucleic acids for detection of HPV sequences.

Abstract: In a method of producing leather comprising a plurality of steps, methanesulfonic acid is used in at least one step.

Abstract: A method is disclosed for the manufacturing of elements of non-ferrous metal alloys, advantageously aluminium alloys, used for the manufacturing of shaped elements, in particular rods, in thermal treatment of metals. The charge will be subjected to plastic working of at least 60% deformation, advantageously by pressing with the degree of processing exceeding the value of 2, at a temperature below the range of occurrence of a solid solution, after which the obtained element undergoes the supersaturation process by heating it up to the temperature of occurrence of a solid solution and keeping it at this temperature for a period of 2-25 minutes, advantageously 5 minutes, and then rapidly cooled, advantageously using water, to the ambient temperature, after which it is subjected to the ageing process.

Abstract: An infrared heating method comprises: wholly infrared heating a steel sheet uniformly up to a temperature which is A3 point or above; and temperature distribution controlling, wherein, after the wholly infrared heating, partial lowering of a light intensity of infrared rays irradiated toward the steel sheet is performed to provide a first region having a temperature of A3 point or above and a second region having a temperature less than A1 point in the steel sheet.

Abstract: [Problem] To provide a raw material steel sheet for providing a high strength nonmagnetic austenitic stainless steel material that has a high elastic limit stress and excellent toughness. [Solution to Problem] An austenitic stainless steel sheet containing 0.12% or less of C, from 0.30 to 3.00% of Si, from 2.0 to 9.0% of Mn, from 7.0 to 15.0% of Ni, from 11.0 to 20.0% of Cr, and 0.30% or less of N, and further containing at least one kind of 3.0% or less of Mo, 1.0% or less of V, 1.0% or less of Nb, 1.0% or less of Ti, and 0.010% or less of B, all in terms of percentage by mass, with the balance of Fe and unavoidable impurities, having a component composition having a Ni equivalent of 19.0 or more, having a value of d?1/2 of 0.40 or more, wherein d (?m) represents an average austenitic crystal grain diameter, and having a property that provides a magnetic permeability of 1.0100 or less after subjected to cold rolling with an equivalent strain of 0.50 or more.

Abstract: A hot-rolled steel sheet has a composition containing: in mass %, C: 0.01 to 0.2%; Si: 2.5% or less; Mn: 4.0% or less; P: 0.10% or less; S: 0.03% or less; Al: 0.001 to 2.0%; N: 0.01% or less; and O: 0.01% or less, and one kind or a total of two kinds of Ti and Nb for 0.01 to 0.30%. An average effective crystal grain diameter at a sheet thickness ¼ part is 10 ?m or less, and an average effective crystal grain diameter at a part of a range of 50 ?m from a surface is 6 ?m or less. A structure of the steel sheet is tempered martensite or lower bainite, and a volume fraction thereof is 90% or more as a total.

Abstract: A steel wire for a spring, in which the sag resistance and the fatigue characteristics are improved by production processes without addition of alloy elements, is provided. The spring has a structure obtained by quenching and tempering and includes a first layer at a surface thereof, a second layer interior to the first layer, and a third layer, which is interior to the second layer and reaches a center of the spring, and the second layer has lower hardness than the first and the third layers.

Abstract: Ferritic stainless steel sheet which is excellent in ridging resistance which comprises, by mass %, Cr: 10 to 30%, Sn: 0.005 to 1%, C: 0.001 to 0.1%, N: 0.001 to 0.1%, Si: 0.01 to 3.0%, Mn: 0.01 to 3.0%, P: 0.005 to 0.1%, and S: 0.0001 to 0.01% and has a balance of Fe and unavoidable impurities and which has an X-ray diffraction strength in the {100}<012> orientation from a surface layer to t/4 (“t” is sheet thickness) of 2 or more.

Abstract: This ferritic stainless steel sheet contains, in terms of % by mass, 0.02% or less of C, 0.02% or less of N, 0.10% to 0.60% of Si, 0.10% to 0.80% of Mn, 15.0% to 21.0% of Cr, more than 2.00% to 3.50% or less of Cu, 0.30% to 0.80% of Nb, 1.00% to 2.50% of Mo, and 0.0003% to 0.0030% of B, with a remainder being Fe and unavoidable impurities, wherein a maximum particle size of ?-Cu that is present in a structure is 20 nm to 200 nm.

Abstract: In order to selectively extract copper and/or lead from an acidic solution containing high concentrations of manganese, etc., the valuable-metal extracting agent of the present invention is expressed by general formula (1). In the formula, R1 and R2 each represent the same or different alkyl groups, R3 represents a hydrogen atom or an alkyl group, and R4 represents a hydrogen atom or a given group, other than an amino group, that bonds with an ? carbon as an amino acid. In general formula (1), the inclusion of a glycine unit, a histidine unit, a lysine unit, an asparagine acid unit, or a normal methylglycine unit is preferred. When using the extracting agent to extract copper/and lead, it is preferable that the pH of the acidic solution be adjusted to 1.0-5.5 inclusive.

Abstract: The present invention provides an additive for tin stripping, comprising 0.1 to 20 wt % of copper corrosion inhibitor and 0.1 to 20 wt % of nickel corrosion inhibitor; wherein said weight percentage is based on the total weight of said additive. The present additive can be used with nitric acid conventionally used for metal-stripping for not only reducing the usage of nitric acid but also improving the efficiency of tin stripping. The present invention also provides a method for Tin recycle and a reaction tank for metal recycle. Both of them are favorable for satisfying the needs of metal recycle (especially, tin recycle) in the field.

Abstract: A copper-zinc alloy, in particular for providing components for a plumbing fitting. The alloy comprises (in % by weight): between 63.0 and 64.5% Cu, between 33.8 and 36.8% Zn, between 0.0 and 0.20% Pb, between 0.2 and 0.7% Al, between 0.04 and 0.14% As, between 0.0 and 0.3% Fe, between 0.0 and 0.3% Sn, between 0.0 and 0.1% Mn, and residual constituents in respective maximum quantities of 0.02%. A method for producing a cast component is provided that includes a copper-zinc alloy of this type. The copper-zinc alloy and the components produced therewith permit a particularly environmentally-friendly, cost-effective production of plumbing fittings.

Abstract: A copper-zinc alloy, in particular for providing components for a plumbing fitting. The alloy includes (in % by weight): between 63.5 and 63.8% Cu, between 35.2 and 35.6 Zn, between 0.17 ans 0.20% Pb, between 0.32 and 0.4% Al, between 0.11 and 0.13% As, between 0.16 and 0.2% Fe, between 0.0 and 0.2% Sn, between 0.0 and 0.2% Mn, and residual constituents in respective maximum quantities of 0.02%. A method for producing a cast component is provided that includes a copper-zinc alloy of this type. The copper-zinc alloy and the components produced therewith permit a particularly environmentally-friendly, cost-effective production of plumbing fittings.

Abstract: Provided are a titanium sheet which combines strength with formability and a plate for plate heat exchangers which was obtained from the titanium sheet. The titanium sheet has a crystal grain structure which comprises an ? phase, and is characterized by containing 0.020-0.150 mass % Fe, 0.020-0.150 mass % O, and 0.002-0.100 mass % C, with the remainder comprising titanium and unavoidable impurities. The sheet is further characterized in that the sum of the contents (mass %) of the Fe and the C is at least 0.80 times the content (mass %) of the O and the concentration of C in the grain boundaries is 1.0 mass % or higher.

Abstract: This application discloses 3XXX aluminum alloys useful in fabricating can ends and tabs used for opening cans, particularly AA3104 and AA3204 aluminum alloys. This application discloses 3XXX aluminum alloys useful in fabricating cans comprising a body, end and tab, particularly AA3104 and AA3204 aluminum alloys.

Abstract: New aluminum-magnesium-lithium alloys, and methods for producing the same are disclosed. The alloys generally contain 2.0-3.9 wt. % Mg, 0.1-1.8 wt. % Li, up to 1.5 wt. % Cu, up to 2.0 wt. % Zn, up to 1.0 wt. % Ag, up to 1.5 wt. % Mn, up to 0.5 wt. % Si, up to 0.35 wt. % Fe, 0.05 to 0.50 wt. % of a grain structure control element, up to 0.10 wt. % Ti, and up to 0.10 wt. % of any other element, with the total of these other elements not exceeding 0.35 wt. %, the balance being aluminum.

Abstract: A rolled aluminum alloy material is provided with excellent strength and press workability and with which a poor and patchy appearance is less likely to occur after the alumite treatment. The rolled aluminum alloy material can be utilized for components of a bicycle crank. The rolled aluminum alloy material has a component composition comprising 0.6-1.4 wt % of Mg, 0.3-1.0 wt % of Si, 0.1-0.5 wt % of Cu, 0.02-0.4 wt % of Cr, and 0.1-0.6 wt % of Mn, and Al and inevitable impurities as the remainder.

Abstract: Disclosed is a 7xxx-series aluminum alloy sheet having a specific chemical composition and produced by a common procedure. The aluminum alloy sheet has a good balance between a Zn content and a Mg content while having a lower Zn content so as to have a strength retained at high level. The aluminum alloy sheet has a microstructure having a specific endothermic peak temperature and a specific maximum height of exothermic peak(s) in a differential scanning calorimetric curve, where the curve is plotted after natural aging of the produced sheet. The aluminum alloy sheet can thereby have a high strength, satisfactory formability, and good corrosion resistance which are required for structural components.

Abstract: High strength forged aluminum alloys and methods for producing the same are disclosed. The forged aluminum alloy products may have grains having a high aspect ratio in at least two planes, generally the L-ST and the LT-ST planes. The forged aluminum alloy products may also have a high amount of texture. The forged products may realize increased strength relative to conventionally prepared forged products of comparable product form, composition and temper.

Abstract: A cemented carbide material comprises WC, between around 3 to around 10 wt. % Co and between around 0.5 to around 8 wt. % Re. The equivalent total carbon (ETC) content of the cemented carbide material with respect to WC is between around 6.3 wt. % to around 6.9 wt. % and the cemented carbide material is substantially free of eta-phase and free carbon. There is also disclosed a method of producing such a material and use of such a material.